Inventiva S.A.: Piper Sandler Sees Enormous Potential in Lanifibranor for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis!
Reading Time: 3 minutes
Inventiva S.A. (IVA) is a biopharmaceutical company focused on oral small-molecule therapies for the treatment of patients with MASH. The company is currently evaluating Lanifibranor, a novel pan-PPAR agonist, in the pivotal Phase 3 study NATiV3 for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Expansion in China through cooperation pays off with milestone payments In July, the company announced the receipt of a milestone payment of $10 million from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
